## IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA

IN RE: GLUGAGON-LIKE : CIVIL ACTION

PEPTIDE-1 RECEPTOR AGONISTS

(GLP-1 RAS) PRODUCTS : LIABILITY LITIGATION :

:

THIS DOCUMENT RELATES TO: : MDL No. 3094

24-md-3094

Middleton v. Novo Nordisk A/S

Case No. 2:24-cv-3166

HON. KAREN SPENCER MARSTON

Rogers v. Novo Nordisk A/S
Case No. 2:24-cv-03177

Case No. 2:24-cv-03177 :

## **ORDER**

**AND NOW**, this 22nd day of July, 2024, in light of the telephonic conferences on July 19, 2024 and July 22, 2024, it is **ORDERED** that *Middleton v. Novo Nordisk A/S* (Case No. 2:24-cv-3166) and *Rogers v. Novo Nordisk A/S* (Case No. 2:24-cv-03177) are **STAYED** pending a decision by the Judicial Panel on Multidistrict Litigation ("the Panel" or "JPML") to transfer them to this MDL. <sup>1</sup>

## IT IS SO ORDERED.

/s/ Karen Spencer Marston
KAREN SPENCER MARSTON, J.

<sup>&</sup>lt;sup>1</sup> Both actions allege injuries caused by Saxenda. Although Saxenda is a GLP-1 RA, it is not one of the drugs included in the Panel's Transfer Order. *See* Doc. No. 1 at 2 (listing Ozempic, Wegovy, Rybelsus, Trulicity, and Mounjaro). The parties must seek the Panel's approval prior to adding a drug to this MDL, notwithstanding the entry of the Direct Filing Order in this case, Case Management Order No. 14, Doc. No. 190. The Court's Direct Filing Order is limited to the drugs approved by the Panel. *See* Doc. No. 190 at 6 ("Actions filed directly in this Court pursuant to this order alleging use of Ozempic, Rybelsus, Wegovy . . . and/or *other drugs as added by the JPML* . . . .") (emphasis added).